Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
Characterization of inhibition of M2 ion channel activity by BL-1743, an inhibitor of influenza A virus.
Tu Q
,
Pinto LH
,
Luo G
,
Shaughnessy MA
,
Mullaney D
,
Kurtz S
,
Krystal M
,
Lamb RA
.
???displayArticle.abstract???
The influenza A virus M2 integral membrane protein has ion channel activity that can be inhibited by the antiviral drug amantadine. Recently, a spirene-containing compound, BL-1743 (2-[3-azaspiro (5,5)undecanol]-2-imidazoline), that inhibits influenza virus growth was identified (S. Kurtz, G. Lao, K. M. Hahnenberger, C. Brooks, O. Gecha, K. Ingalls, K.-I. Numata, and M. Krystal, Antimicrob. Agents Chemother. 39:2204-2209, 1995). We have examined the ability of BL-1743 to inhibit the M2 ion channel when expressed in oocytes of Xenopus laevis. BL-1743 inhibition is complete as far as can be measured by electrophysiological methods and is reversible, with a reverse reaction rate constant of 4.0 x 10(-3) s(-1). In contrast, amantadine inhibition is irreversible within the time frame of the experiment. However, BL-1743 inhibition and amantadine inhibition have similar properties. The majority of isolated influenza viruses resistant to BL-1743 are also amantadine resistant. In addition, all known amino acid changes which result in amantadine resistance also confer BL-1743 resistance. However, one BL-1743-resistant virus isolated, designated M2-I35T, contained the change Ile-35-->Thr. This virus is >70-fold more resistant to BL-1743 and only 10-fold more resistant to amantadine than the wild-type virus. When the ion channel activity of M2-I35T was examined in oocytes, it was found that M2-I35T is BL-1743 resistant but is reversibly inhibited by amantadine. These findings suggest that these two drugs interact differently with the M2 protein transmembrane pore region.
Black,
Production of the M2 protein of influenza A virus in insect cells is enhanced in the presence of amantadine.
1993, Pubmed
Black,
Production of the M2 protein of influenza A virus in insect cells is enhanced in the presence of amantadine.
1993,
Pubmed
Duff,
The transmembrane domain of influenza A M2 protein forms amantadine-sensitive proton channels in planar lipid bilayers.
1992,
Pubmed
Duff,
Neutron diffraction reveals the site of amantadine blockade in the influenza A M2 ion channel.
1994,
Pubmed
Giffin,
Novel assay for the influenza virus M2 channel activity.
1995,
Pubmed
,
Xenbase
Guinea,
Influenza virus M2 protein modifies membrane permeability in E. coli cells.
1994,
Pubmed
Hay,
The molecular basis of the specific anti-influenza action of amantadine.
1985,
Pubmed
Holsinger,
Influenza virus M2 integral membrane protein is a homotetramer stabilized by formation of disulfide bonds.
1991,
Pubmed
Holsinger,
Analysis of the posttranslational modifications of the influenza virus M2 protein.
1995,
Pubmed
,
Xenbase
Hull,
Integration of a small integral membrane protein, M2, of influenza virus into the endoplasmic reticulum: analysis of the internal signal-anchor domain of a protein with an ectoplasmic NH2 terminus.
1988,
Pubmed
Kurtz,
Growth impairment resulting from expression of influenza virus M2 protein in Saccharomyces cerevisiae: identification of a novel inhibitor of influenza virus.
1995,
Pubmed
Lamb,
Influenza virus M2 protein is an integral membrane protein expressed on the infected-cell surface.
1985,
Pubmed
Ohuchi,
Rescue of vector-expressed fowl plague virus hemagglutinin in biologically active form by acidotropic agents and coexpressed M2 protein.
1994,
Pubmed
Paterson,
RNA editing by G-nucleotide insertion in mumps virus P-gene mRNA transcripts.
1990,
Pubmed
Ritchey,
RNAs of influenza A, B, and C viruses.
1976,
Pubmed
Sanger,
DNA sequencing with chain-terminating inhibitors.
1977,
Pubmed
Schroeder,
Functional reconstitution in lipid vesicles of influenza virus M2 protein expressed by baculovirus: evidence for proton transfer activity.
1994,
Pubmed
Shimbo,
Ion selectivity and activation of the M2 ion channel of influenza virus.
1996,
Pubmed
,
Xenbase
Sugrue,
Specific structural alteration of the influenza haemagglutinin by amantadine.
1990,
Pubmed
Sugrue,
Structural characteristics of the M2 protein of influenza A viruses: evidence that it forms a tetrameric channel.
1991,
Pubmed
Takeuchi,
Influenza virus M2 protein ion channel activity stabilizes the native form of fowl plague virus hemagglutinin during intracellular transport.
1994,
Pubmed
Tosteson,
Reconstitution of the influenza virus M2 ion channel in lipid bilayers.
1994,
Pubmed
,
Xenbase
Wang,
Direct measurement of the influenza A virus M2 protein ion channel activity in mammalian cells.
1994,
Pubmed
Wang,
Activation of the M2 ion channel of influenza virus: a role for the transmembrane domain histidine residue.
1995,
Pubmed
,
Xenbase
Wang,
Ion channel activity of influenza A virus M2 protein: characterization of the amantadine block.
1993,
Pubmed
,
Xenbase
Zebedee,
Influenza A virus M2 protein: monoclonal antibody restriction of virus growth and detection of M2 in virions.
1988,
Pubmed
Zebedee,
Characterization of the influenza virus M2 integral membrane protein and expression at the infected-cell surface from cloned cDNA.
1985,
Pubmed
